"Fewer Americans are dying from cancer.
This is one main take-away from the latest report on cancer death rates and new diagnoses of cancer in the U.S. This decline is seen among men and women across all major racial and ethnic groups,"...
Three patients received 10,000 International Units/m² of Oncaspar® as an intravenous infusion. One patient experienced a slight increase in liver enzymes. A second patient developed a rash 10 minutes after the start of the infusion, which was controlled with the administration of an antihistamine and by slowing down the infusion rate. A third patient did not experience any adverse reactions.
- History of serious allergic reactions to Oncaspar® .
- History of serious thrombosis with prior L-asparaginase therapy.
- History of pancreatitis with prior L-asparaginase therapy.
- History of serious hemorrhagic events with prior L-asparaginase therapy.
Last reviewed on RxList: 5/2/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Oncaspar Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.